The Experts below are selected from a list of 184590 Experts worldwide ranked by ideXlab platform

Joel Coste - One of the best experts on this subject based on the ideXlab platform.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention. Methods and results A population-based cohort study using French national healthcare databases was performed, studying all subjects who turned 75 in 2012-14, with no history of Cardiovascular disease and with a statin medication possession ratio ≥80% in each of the previous 2 years. Statin discontinuation was defined as three consecutive months without exposure. The outcome was hospital admission for Cardiovascular event. The hazard ratio comparing statin discontinuation with continuation was estimated using a marginal structural model adjusting for both baseline and time-varying covariates (Cardiovascular drug use, comorbidities, and frailty indicators). A total of 120 173 subjects were followed for an average of 2.4 years, of whom 17 204 (14.3%) discontinued statins and 5396 (4.5%) were admitted for a Cardiovascular event. The adjusted hazard ratios for statin discontinuation were 1.33 [95% confidence interval (CI) 1.18-1.50] (any Cardiovascular event), 1.46 (95% CI 1.21-1.75) (coronary event), 1.26 (95% CI 1.05-1.51) (cerebrovascular event), and 1.02 (95% CI 0.74-1.40) (other vascular event). Conclusion Statin discontinuation was associated with a 33% increased risk of admission for Cardiovascular event in 75-year-old primary prevention patients. Future studies, including randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention.

Philippe Giral - One of the best experts on this subject based on the ideXlab platform.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention. Methods and results A population-based cohort study using French national healthcare databases was performed, studying all subjects who turned 75 in 2012-14, with no history of Cardiovascular disease and with a statin medication possession ratio ≥80% in each of the previous 2 years. Statin discontinuation was defined as three consecutive months without exposure. The outcome was hospital admission for Cardiovascular event. The hazard ratio comparing statin discontinuation with continuation was estimated using a marginal structural model adjusting for both baseline and time-varying covariates (Cardiovascular drug use, comorbidities, and frailty indicators). A total of 120 173 subjects were followed for an average of 2.4 years, of whom 17 204 (14.3%) discontinued statins and 5396 (4.5%) were admitted for a Cardiovascular event. The adjusted hazard ratios for statin discontinuation were 1.33 [95% confidence interval (CI) 1.18-1.50] (any Cardiovascular event), 1.46 (95% CI 1.21-1.75) (coronary event), 1.26 (95% CI 1.05-1.51) (cerebrovascular event), and 1.02 (95% CI 0.74-1.40) (other vascular event). Conclusion Statin discontinuation was associated with a 33% increased risk of admission for Cardiovascular event in 75-year-old primary prevention patients. Future studies, including randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention.

Siyan Zhan - One of the best experts on this subject based on the ideXlab platform.

  • the Cardiovascular Effect of incretin based therapies among type 2 diabetes a systematic review and network meta analysis
    Expert Opinion on Drug Safety, 2018
    Co-Authors: Andrea Cipriani, Zhirong Yang, Jun Yang, Ting Cai, Xiaochi Quan, Yuan Zhang, Sanbao Chai, Feng Sun, Siyan Zhan
    Abstract:

    ABSTRACTObjective: To evaluate the comparative Cardiovascular safety of incretin-based therapies in patients with type 2 diabetes mellitus (T2DM).Methods: Medline, Embase, the Cochrane Library and www.clinicaltrials.gov were searched for randomized controlled trials (RCTs) with duration≥12 weeks. Network meta-analysis was performed, followed by subgroup analysis and meta-regression. The Grading of Recommendations Assessment, Development and Evaluation system was used to assess the quality of evidence. The outcome of interest was a composite of Cardiovascular death, myocardial infarction, stroke and heart failure. Odds ratio (OR) with 95% confidence interval (CI) was calculated as the measure of Effect size.Results: 281 RCTs (76.9% double-blinded) with 180,000 patients were included, comparing incretin-based therapies with other six classes of anti-diabetic drugs or placebo. A statistically significant reduction in the risk of Cardiovascular events was found in favour of GLP-1RAs when compared with placebo...

A Weill - One of the best experts on this subject based on the ideXlab platform.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention. Methods and results A population-based cohort study using French national healthcare databases was performed, studying all subjects who turned 75 in 2012-14, with no history of Cardiovascular disease and with a statin medication possession ratio ≥80% in each of the previous 2 years. Statin discontinuation was defined as three consecutive months without exposure. The outcome was hospital admission for Cardiovascular event. The hazard ratio comparing statin discontinuation with continuation was estimated using a marginal structural model adjusting for both baseline and time-varying covariates (Cardiovascular drug use, comorbidities, and frailty indicators). A total of 120 173 subjects were followed for an average of 2.4 years, of whom 17 204 (14.3%) discontinued statins and 5396 (4.5%) were admitted for a Cardiovascular event. The adjusted hazard ratios for statin discontinuation were 1.33 [95% confidence interval (CI) 1.18-1.50] (any Cardiovascular event), 1.46 (95% CI 1.21-1.75) (coronary event), 1.26 (95% CI 1.05-1.51) (cerebrovascular event), and 1.02 (95% CI 0.74-1.40) (other vascular event). Conclusion Statin discontinuation was associated with a 33% increased risk of admission for Cardiovascular event in 75-year-old primary prevention patients. Future studies, including randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention.

Anke Neumann - One of the best experts on this subject based on the ideXlab platform.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention. Methods and results A population-based cohort study using French national healthcare databases was performed, studying all subjects who turned 75 in 2012-14, with no history of Cardiovascular disease and with a statin medication possession ratio ≥80% in each of the previous 2 years. Statin discontinuation was defined as three consecutive months without exposure. The outcome was hospital admission for Cardiovascular event. The hazard ratio comparing statin discontinuation with continuation was estimated using a marginal structural model adjusting for both baseline and time-varying covariates (Cardiovascular drug use, comorbidities, and frailty indicators). A total of 120 173 subjects were followed for an average of 2.4 years, of whom 17 204 (14.3%) discontinued statins and 5396 (4.5%) were admitted for a Cardiovascular event. The adjusted hazard ratios for statin discontinuation were 1.33 [95% confidence interval (CI) 1.18-1.50] (any Cardiovascular event), 1.46 (95% CI 1.21-1.75) (coronary event), 1.26 (95% CI 1.05-1.51) (cerebrovascular event), and 1.02 (95% CI 0.74-1.40) (other vascular event). Conclusion Statin discontinuation was associated with a 33% increased risk of admission for Cardiovascular event in 75-year-old primary prevention patients. Future studies, including randomized studies, are needed to confirm these findings and support updating and clarification of guidelines on the use of statins for primary prevention in the elderly.

  • Cardiovascular Effect of discontinuing statins for primary prevention at the age of 75 years a nationwide population based cohort study in france
    European Heart Journal, 2019
    Co-Authors: Philippe Giral, Anke Neumann, A Weill, Joel Coste
    Abstract:

    Aims The role of statin therapy in primary prevention of Cardiovascular disease in persons older than 75 years remains a subject of debate with little evidence to support or exclude the benefit of this treatment. We assessed the Effect of statin discontinuation on Cardiovascular outcomes in previously adherent 75-year-olds treated for primary prevention.